Publications tagged with “propensity score”
An analytic method often used to balance observed baseline characteristics in study cohorts through matching or weighting.
- Long MD, Ball K, Bocage C, Kappelman MD, Pipkin CA, Parlett LE. Novel therapies for inflammatory bowel disease and risks for non-melanoma skin cancer. Podium presented at: 2025 Digestive Disease Week; May 03 – May 06, 2025; San Diego, CA, US .
- Cook M, Beachler DC, Parlett LE, Cochetti PT, Finkle WD, Lanes S. Abstract 5050: testosterone supplementation in relation to prostate cancer in a us commercial insurance claims database. Poster presented at: 2019 American Association for Cancer Research (AACR) Annual Meeting; Mar 29 – Apr 03, 2019; Atlanta, GA, US https://aacrjournals.org/cancerres/article/79/13_Supplement/5050/636990/Abstract-5050-Testosterone-supplementation-in. doi: 10.1158/1538-7445.AM2019-5050.
- Parlett LE, Ball K, Pipkin CA, Kappelman MD, Bocage C, Long MD. Compared to thiopurines and tumor necrosis factor inhibitors novel biologics are associated with reduced risk of non-melanoma skin cancer among patients with inflammatory bowel disease. Poster presented at: 2024 International Society for Pharmacoepidemiology Annual Meeting; Aug 24 – Aug 28, 2024; Berlin, DE .
- Kappelman MD, Adimadhyam S, Hou L, et al. Real-world evidence comparing vedolizumab and ustekinumab in antitumor necrosis factor-experienced patients with crohn's disease. Am J Gastroenterol. 2023; 118 (4) :674-84 doi: 10.14309/ajg.0000000000002068.
- Cook M, Beachler DC, Parlett LE, et al. Testosterone therapy in relation to prostate cancer in a U.S. commercial insurance claims database. Cancer Epidemiol Biomarkers Prev. 2020; 29 (1) :236-45 doi: 10.1158/1055-9965.EPI-19-0619.
- Parlett LE, Gordon A, Sylwestrzak G, White J, Power T, Barron J. Hospitalization rates and costs among real world users of sacubitril/valsartan versus other heart failure medications. Podium presented at: 2018 American Heart Association Scientific Sessions; Nov 10 – Nov 12, 2018; Chicago, IL, US .